Time course of serum lipids and apolipoproteins after acute myocardial infarction: modification by pravastatin.
Pravastatin was administered to patients suffering an acute myocardial infarction starting with a dose of 10 mg/day at day 3 and continuing with a dose of 20 mg/day up to a period of 3 months. The study was performed on the basis of a randomized placebo-controlled double-blind trial. At the dosage used pravastatin significantly lowered the total cholesterol and LDL-cholesterol levels and increased the HDL-cholesterol levels compared to placebo. A prospective clinical trial in order to examine the possible clinical relevance of these findings is recommended.
Kesteloot
H
H
Department of Epidemiology and Biostatistics, K.U. Leuven, Belgium.
Claeys
G
G
Blanckaert
N
N
Lesaffre
E
E
D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001053:Apolipoproteins / Q000097:blood* / Q000187:drug effects; D008076:Cholesterol, HDL / Q000187:drug effects / Q000378:metabolism; D008078:Cholesterol, LDL / Q000187:drug effects / Q000378:metabolism; D003404:Creatinine / Q000097:blood / Q000378:metabolism; D004311:Double-Blind Method; D006801:Humans; D008055:Lipids / Q000097:blood*; D009203:Myocardial Infarction / Q000097:blood* / Q000188:drug therapy*; D017035:Pravastatin / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D000924:Anticholesteremic Agents; D001053:Apolipoproteins; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D008055:Lipids; D003404:Creatinine; D017035:Pravastatin